Athersys (ATHX) Raised to Sell at BidaskClub

Athersys (NASDAQ:ATHX) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday, BidAskClub reports.

Several other equities research analysts have also commented on ATHX. Zacks Investment Research lowered Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. Maxim Group set a $8.00 target price on Athersys and gave the company a “buy” rating in a research note on Wednesday, January 23rd. Finally, ValuEngine upgraded Athersys from a “hold” rating to a “buy” rating in a research note on Friday, January 25th.

Shares of NASDAQ:ATHX opened at $1.97 on Friday. Athersys has a 12 month low of $1.35 and a 12 month high of $3.09.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). The company had revenue of $1.45 million during the quarter. Athersys had a negative return on equity of 58.10% and a negative net margin of 109.78%.

Hedge funds have recently bought and sold shares of the company. Allred Capital Management LLC acquired a new stake in shares of Athersys in the fourth quarter valued at about $74,000. Marshall Wace LLP acquired a new stake in shares of Athersys in the third quarter valued at about $59,000. BlackRock Inc. grew its stake in shares of Athersys by 12.8% in the third quarter. BlackRock Inc. now owns 6,769,421 shares of the biopharmaceutical company’s stock valued at $14,217,000 after buying an additional 768,755 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Athersys in the first quarter valued at about $36,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of Athersys in the fourth quarter valued at about $47,000. Institutional investors and hedge funds own 19.47% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Further Reading: How to Trade Using Analysts Ratings

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.